1
|
Dunaliella salina as a Potential Biofactory for Antigens and Vehicle for Mucosal Application. Processes (Basel) 2022. [DOI: 10.3390/pr10091776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The demand for effective, low-cost vaccines increases research in next-generation biomanufacturing platforms and the study of new vaccine delivery systems (e.g., mucosal vaccines). Applied biotechnology in antigen production guides research toward developing genetic modification techniques in different biological models to achieve the expression of heterologous proteins. These studies are based on various transformation protocols, applied in prokaryotic systems such as Escherichia coli to eukaryotic models such as yeasts, insect cell cultures, animals, and plants, including a particular type of photosynthetic organisms: microalgae, demonstrating the feasibility of recombinant protein expression in these biological models. Microalgae are one of the recombinant protein expression models with the most significant potential and studies in the last decade. Unicellular photosynthetic organisms are widely diverse with biological and growth-specific characteristics. Some examples of the species with commercial interest are Chlamydomonas, Botryococcus, Chlorella, Dunaliella, Haematococcus, and Spirulina. The production of microalgae species at an industrial level through specialized equipment for this purpose allows for proposing microalgae as a basis for producing recombinant proteins at a commercial level. A specie with a particular interest in biotechnology application due to growth characteristics, composition, and protein production capacity is D. salina, which can be cultivated under industrial standards to obtain βcarotene of high interest to humans. D saline currently has advantages over other microalgae species, such as its growth in culture media with a high salt concentration which reduces the risk of contamination, rapid growth, generally considered safe (GRAS), recombinant protein biofactory, and a possible delivery vehicle for mucosal application. This review discusses the status of microalgae D. salina as a platform of expression of recombinant production for its potential mucosal application as a vaccine delivery system, taking an advance on the technology for its production and cultivation at an industrial level.
Collapse
|
2
|
Khalid F, Tahir R, Ellahi M, Amir N, Rizvi SFA, Hasnain A. Emerging trends of edible vaccine therapy for combating human diseases especially
COVID
‐19: Pros, cons, and future challenges. Phytother Res 2022; 36:2746-2766. [PMID: 35499291 PMCID: PMC9347755 DOI: 10.1002/ptr.7475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 03/18/2022] [Accepted: 04/06/2022] [Indexed: 11/07/2022]
Abstract
The researchers are still doing efforts to develop an effective, reliable, and easily accessible vaccine candidate to protect against COVID‐19. As of the August 2020, nearly 30 conventional vaccines have been emerged in clinical trials, and more than 200 vaccines are in various development stages. Nowadays, plants are also considered as a potential source for the production of monoclonal antibodies, vaccines, drugs, immunomodulatory proteins, as well as used as bioreactors or factories for their bulk production. The scientific evidences enlighten that plants are the rich source of oral vaccines, which can be given either by eating the edible parts of plants and/or by oral administration of highly refined proteins. The use of plant‐based edible vaccines is an emerging trend as it possesses minimum or no side effects compared with synthetic vaccines. This review article gives insights into different types of vaccines, the use of edible vaccines, advantages of edible vaccines over conventional vaccines, and mechanism of action of edible vaccines. This review article also focuses on the applications of edible vaccines in wide‐range of human diseases especially against COVID‐19 with emphasis on future perspectives of the use of edible vaccines.
Collapse
Affiliation(s)
- Fatima Khalid
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
| | - Reema Tahir
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
| | - Manahil Ellahi
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
| | - Nilofer Amir
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
| | - Syed Faheem Askari Rizvi
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
- College of Chemistry and Chemical EngineeringLanzhou UniversityLanzhouP.R. China
| | - Ammarah Hasnain
- Institute of Molecular Biology and BiotechnologyThe University of LahoreLahorePakistan
| |
Collapse
|
3
|
Lucero MS, Chimeno Zoth S, Jaton J, Gravisaco MJ, Pinto S, Richetta M, Berinstein A, Gómez E. Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease. FRONTIERS IN PLANT SCIENCE 2021; 12:741469. [PMID: 34868126 PMCID: PMC8636702 DOI: 10.3389/fpls.2021.741469] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 10/18/2021] [Indexed: 06/13/2023]
Abstract
Infectious bursal disease virus (IBDV) is the etiological agent of an immunosuppressive and highly contagious disease that affects young birds causing important economic losses in the poultry industry worldwide. We have previously developed a plant-based vaccine candidate for infectious bursal disease (IBD) that is able to protect against infection with IBDV when administered through intramuscular (im) route. Given that oral vaccination is non-invasive and stimulates the immunity of the mucosal gastrointestinal surface, the initial site of contact and entry of IBDV, the aim of this work was to study if our immunogen was also able to elicit a protective immune response when orally administered. We demonstrated that 85% of the animals that received two oral doses of the vaccine formulation and all animals that were orally boosted after an im prime scheme developed virus neutralizing antibodies and were protected against IBDV infection, evidenced by the bursa/body weight (BB) ratio, absence of T-cell infiltration, and low viral load in bursa. Although mild to moderate bursal damage was observed in some of these animals, these lesions were not as severe as the ones observed in challenged control groups, which also presented signs of acute inflammation, bursal atrophy, T-cell infiltration, and absence of viral clearance. These results show that two immunizations with our recombinant immunogen are able to induce a specific and protective immune response in chicken against IBDV when orally administered in a prime/boost scheme or when the oral boost follows an im prime scheme. In conclusion, our oral plant-based vaccine candidate could represent a viable alternative to conventional vaccines and is of great interest to the poultry industry.
Collapse
Affiliation(s)
- María Soledad Lucero
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Silvina Chimeno Zoth
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Juan Jaton
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - María José Gravisaco
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Silvina Pinto
- Cátedra de Patología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Matías Richetta
- Gerencia de Gestión Estratégica de Procesos Complementarios, Centro de Investigación en Ciencias Veterinarias y Agronómicas, INTA, Buenos Aires, Argentina
| | - Analía Berinstein
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Evangelina Gómez
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| |
Collapse
|
4
|
Ramos-Vega A, Monreal-Escalante E, Dumonteil E, Bañuelos-Hernández B, Angulo C. Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease. Expert Rev Vaccines 2021; 20:1373-1388. [PMID: 33612044 DOI: 10.1080/14760584.2021.1893170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Introduction: Three decades of evidence have demonstrated that plants are an affordable platform for biopharmaceutical production and delivery. For instance, several plant-made recombinant proteins have been approved for commercialization under good manufacturing practice (GMP). Thus far, plant-based vaccine prototypes have been evaluated at pre- and clinical levels. Particularly, plant-made vaccines against parasitic diseases, such as malaria, cysticercosis, and toxoplasmosis have been successfully produced and orally delivered with promising outcomes in terms of immunogenicity and protection. The experience on several approaches and technical strategies over 30 years accounts for their potential low-cost, high scalability, and easy administration.Areas covered: This platform is an open technology to fight against Chagas disease, one of the most important neglected tropical diseases worldwide.Expert opinion: This review provides a perspective for the potential use of plants as a production platform and delivery system of Trypanosoma cruzi recombinant antigens, analyzing the advantages and limitations with respect to plant-made vaccines produced for other parasitic diseases. Plant-made vaccines are envisioned to fight against Chagas disease and other neglected tropical diseases in those countries suffering endemic prevalence.
Collapse
Affiliation(s)
- Abel Ramos-Vega
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México
| | - Elizabeth Monreal-Escalante
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México.,CONACYT- Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p, México
| | - Eric Dumonteil
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne and Infectious Disease Research Center, Tulane University, New Orleans, LA, USA
| | - Bernardo Bañuelos-Hernández
- Facultad de Agronomía Y Veterinaria, Universidad de La Salle Bajio, Avenida Universidad 602, Lomas del Campestre, León Guanajuato, México
| | - Carlos Angulo
- Grupo de Inmunología & Vacunología. Centro de Investigaciones Biológicas del Noroeste, S.C. (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, B.c.s. C.p., México
| |
Collapse
|
5
|
Cebadera Miranda E, Castillo Ruiz-Cabello MV, Cámara Hurtado M. Food biopharmaceuticals as part of a sustainable bioeconomy: Edible vaccines case study. N Biotechnol 2020; 59:74-79. [PMID: 32688060 DOI: 10.1016/j.nbt.2020.06.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 06/22/2020] [Accepted: 06/25/2020] [Indexed: 12/21/2022]
Abstract
The lack of immunization in developing countries is undoubtedly the most serious consequence of the difficulty in accessing traditional vaccination systems. The World Health Organization (WHO) has aimed to find low-cost vaccines, which are accessible to the population and are easy to store and distribute without the need for refrigeration. There is literature support that orally administered edible vaccines are promising agents to reduce the incidence of diseases such as hepatitis and diarrhoea, especially in the developing world. This article focuses on the study of the suitability of edible vaccines as biopharmaceuticals in the context of the 2030 Agenda for Sustainable Development, allowing to comprehensively address both malnutrition and the degree of immunization, mainly in the child population in developing countries. This is embedded within the scope of a new concept promulgated by the UN and FAO called' Therapeutic Food' or 'Ready to Use Therapeutic Food'. Biopharmaceuticals such as edible processed vaccines have the potential to play an important role in increasing global health to achieve the 2030 - Sustainable Development Goals (SDGs), and beyond, as a solution to the dual problem of malnutrition and immunoprophylaxis as part of a sustainable bioeconomy. This article reviews their most promising applications, as well as the problems of a scientific and socioeconomic nature, including the complex current legislation that restricts their implementation.
Collapse
Affiliation(s)
- Elena Cebadera Miranda
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain
| | - Mª Victoria Castillo Ruiz-Cabello
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain
| | - Montaña Cámara Hurtado
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain.
| |
Collapse
|
6
|
Saito S, Takagi H, Wakasa Y, Ozawa K, Takaiwa F. Safety and efficacy of rice seed-based oral allergy vaccine for Japanese cedar pollinosis in Japanese monkeys. Mol Immunol 2020; 125:63-69. [DOI: 10.1016/j.molimm.2020.06.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 06/17/2020] [Accepted: 06/18/2020] [Indexed: 11/26/2022]
|
7
|
Ibrahim EH, Taha R, Ghramh HA, Kilany M. Development of Rift Valley fever (RVF) vaccine by genetic joining of the RVF-glycoprotein Gn with the strong adjuvant subunit B of cholera toxin (CTB) and expression in bacterial system. Saudi J Biol Sci 2019; 26:1676-1681. [PMID: 31762643 PMCID: PMC6864185 DOI: 10.1016/j.sjbs.2018.08.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 08/19/2018] [Accepted: 08/20/2018] [Indexed: 12/31/2022] Open
Abstract
One of the mosquito-borne zoonotic diseases is the Rift Valley fever virus (RVFV). Currently, there is no completely licensed vaccine that can be used to vaccinate animals or humans outside endemic areas. The aim of this work was to use the RVFV glycoprotein (Gn) and the subunit B of cholera toxin (CTB) at gene level and build up fused recombinant vaccine. The gene of CTB was joined to the gene Gn to work as an adjuvant in the resulting fusion protein. The designed merged genes (CTB-Gn) was tested for restriction sites, open reading frames, expected fusion protein tertiary structure and antigenicity using computer software. The insert sequence was submitted to the BioProject (GenBank). The insert was subcloned into the pQE-31 expression plasmid. The target recombinant protein (rCTB-Gn) was expressed in M15 bacteria, purified and identified by protein gel electrophoresis. The insert got the accession No: PRJNA386723. Analysis of the designed rCTB-Gn protein revealed that it had the right 3D structure, immunogenic and at the correct molecular weight. The presence of the CTB in the proposed vaccine will augment its immunogenicity. Doses and protection levels of the vaccine need to be manipulated.
Collapse
Affiliation(s)
- Essam H. Ibrahim
- Biology Department, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
- Blood Products Quality Control and Research Department, National Organization for Research and Control of Biologicals, Cairo, Egypt
| | - Ramadan Taha
- Biology Department, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
- Department of Clinical Pathology, Faculty of Veterinary Medicine, Suez Canal University, Egypt
| | - Hamed A. Ghramh
- Biology Department, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
- Research Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
- Unit of Bee Research and Honey Production, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia
| | - Mona Kilany
- Biology Department, Faculty of Sciences and Arts, King Khalid University, Dhahran Al Janoub, Saudi Arabia
- Department of Microbiology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt
| |
Collapse
|
8
|
Bai G, Tian Y, Wu J, Gu Y, Chen Z, Zeng F, Liu J. Construction of a fusion anti-caries DNA vaccine in transgenic tomato plants for PAcA gene and cholera toxin B subunit. Biotechnol Appl Biochem 2019; 66:924-929. [PMID: 31434162 DOI: 10.1002/bab.1806] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 08/20/2019] [Indexed: 11/10/2022]
Abstract
Chronic bacterial infections in the oral cavity influence the development of dental caries. Mutans streptococci are the major pathogenic cause of dental caries. The World Health Organization (WHO) ranks dental caries, cancer, and cardiovascular diseases as the three major global diseases that need urgent preventative and curative measures. However, substantial evidence suggests that traditional prevention and treatment strategies are inefficient in reducing the prevalence of dental caries. For protection against caries, it is important to develop effective vaccines that induce anticolonizing immunity against Streptococcus mutans infections. In the present investigation, we constructed a fusion anti-caries DNA vaccine (PAcA-ctxB) through fusing A region of cell surface protein PAc (PAcA) coding gene of mutans streptococci with cholera toxin B subunit coding gene (CTB). Afterward, the plasmids were integrated into tomato genomes through agrobacterium-mediated plant transformation technology. The presence of transgenes in the tomato genome was confirmed by PCR, β-glucuronidase gene (GUS), and western blot. The expression of genes was confirmed at transcription and protein level. Altogether, the results presented herein showed that transgenic tomatoes may provide a useful system for the production of human caries antigen.
Collapse
Affiliation(s)
- Guohui Bai
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China
| | - Yuan Tian
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China.,Hospital of Stomatology, Zunyi Medical University, Zunyi, People's Republic of China
| | - Jiayuan Wu
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China.,Hospital of Stomatology, Zunyi Medical University, Zunyi, People's Republic of China
| | - Yu Gu
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China
| | - Zhu Chen
- Guiyang Hospital of Stomatology, Guiyang, People's Republic of China
| | - Fengjiao Zeng
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China.,Hospital of Stomatology, Zunyi Medical University, Zunyi, People's Republic of China
| | - Jianguo Liu
- Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, People's Republic of China
| |
Collapse
|
9
|
van Eerde A, Gottschamel J, Bock R, Hansen KEA, Munang'andu HM, Daniell H, Liu Clarke J. Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development. PLANT BIOTECHNOLOGY JOURNAL 2019; 17:1408-1417. [PMID: 30578710 PMCID: PMC6576073 DOI: 10.1111/pbi.13065] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 12/07/2018] [Accepted: 12/12/2018] [Indexed: 05/19/2023]
Abstract
Dengue fever is a mosquito (Aedes aegypti) -transmitted viral disease that is endemic in more than 125 countries around the world. There are four serotypes of the dengue virus (DENV 1-4) and a safe and effective dengue vaccine must provide protection against all four serotypes. To date, the first vaccine, Dengvaxia (CYD-TDV), is available after many decades' efforts, but only has moderate efficacy. More effective and affordable vaccines are hence required. Plants offer promising vaccine production platforms and food crops offer additional advantages for the production of edible human and animal vaccines, thus eliminating the need for expensive fermentation, purification, cold storage and sterile delivery. Oral vaccines can elicit humoural and cellular immunity via both the mucosal and humoral immune systems. Here, we report the production of tetravalent EDIII antigen (EDIII-1-4) in stably transformed lettuce chloroplasts. Transplastomic EDIII-1-4-expressing lettuce lines were obtained and homoplasmy was verified by Southern blot analysis. Expression of EDIII-1-4 antigens was demonstrated by immunoblotting, with the EDIII-1-4 antigen accumulating to 3.45% of the total protein content. Immunological assays in rabbits showed immunogenicity of EDIII-1-4. Our in vitro gastrointestinal digestion analysis revealed that EDIII-1-4 antigens are well protected when passing through the oral and gastric digestion phases but underwent degradation during the intestinal phase. Our results demonstrate that lettuce chloroplast engineering is a promising approach for future production of an affordable oral dengue vaccine.
Collapse
Affiliation(s)
- André van Eerde
- NIBIO – Norwegian Institute of Bioeconomy ResearchDivision of Biotechnology and Plant HealthÅsNorway
| | - Johanna Gottschamel
- NIBIO – Norwegian Institute of Bioeconomy ResearchDivision of Biotechnology and Plant HealthÅsNorway
| | - Ralph Bock
- Max Planck Institute of Molecular Plant PhysiologyPotsdam‐GolmGermany
| | | | | | - Henry Daniell
- Department of BiochemistrySchool of Dental MedicineUniversity of PennsylvaniaPhiladelphiaPAUSA
| | - Jihong Liu Clarke
- NIBIO – Norwegian Institute of Bioeconomy ResearchDivision of Biotechnology and Plant HealthÅsNorway
| |
Collapse
|
10
|
Abstract
Plants and their rich variety of natural compounds are used to maintain and to improve health since the earliest stages of civilization. Despite great advances in synthetic organic chemistry, one fourth of present-day drugs have still a botanical origin, and we are currently living a revival of interest in new pharmaceuticals from plant sources. Modern biotechnology has defined the potential of plants to be systems able to manufacture not only molecules naturally occurring in plants but also newly engineered compounds, from small to complex protein molecules, which may originate even from non-plant sources. Among these compounds, pharmaceuticals such as vaccines, antibodies and other therapeutic or prophylactic entities can be listed. For this technology, the term plant molecular farming has been coined with reference to agricultural applications due to the use of crops as biofactories for the production of high-added value molecules. In this perspective, edible plants have also been thought as a tool to deliver by the oral route recombinant compounds of medical significance for new therapeutic strategies. Despite many hurdles in establishing regulatory paths for this “novel” biotechnology, plants as bioreactors deserve more attention when considering their intrinsic advantages, such as the quality and safety of the recombinant molecules that can be produced and their potential for large-scale and low-cost production, despite worrying issues (e.g. amplification and diffusion of transgenes) that are mainly addressed by regulations, if not already tackled by the plant-made products already commercialized. The huge benefits generated by these valuable products, synthesized through one of the safest, cheapest and most efficient method, speak for themselves. Milestone for plant-based recombinant protein production for human health use was the approval in 2012 by the US Food and Drug Administration of plant-made taliglucerase alfa, a therapeutic enzyme for the treatment of Gaucher’s disease, synthesized in carrot suspension cultures by Protalix BioTherapeutics. In this review, we will go through the various approaches and results for plant-based production of proteins and recent progress in the development of plant-made pharmaceuticals (PMPs) for the prevention and treatment of human diseases. An analysis on acceptance of these products by public opinion is also tempted.
Collapse
|
11
|
Genetic fusion of tetanus toxin fragment C (Hc) gene to cholera toxin subunit B (CTB) gene as a preparatory step for double vaccine production. GENE REPORTS 2018. [DOI: 10.1016/j.genrep.2017.11.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
12
|
Abstract
Molecular farming provides an unprecedented approach for the production of metabolites or proteins of medicinal value from plants used previously only in agricultural setting. These plants act as protein factories that can synthesize a variety of proteins free from pathogens such as plasma proteins, growth factors, and vaccines. This method provides a novel, tempting, inexpensive, easy, and safe alternative to other techniques of protein or antigen production. With the advent of transgenic plants, it is possible to produce unlimited amounts of subunit vaccines (for oral use/edible and of parenteral use), protein used for pharmaceutical/medicinal purpose, recombinant proteins, antibodies, and industrial enzymes. Plants have numerous advantages over the production systems on account of scalability, safety, and are economic; for example, less cost of production is involved for Hepatitis B nucleocapsid antigen using transgenic tobacco. Biopharming or molecular farming provides an important resource for cheaper drug production used in the treatment of cancer, heart diseases, and infectious diseases. The pharmaceutical products are manufactured by genetically engineered plants that are extracted and purified, also known as pharmaceuticals produced by plants. Edible vaccines are cheaper in cost, easy to administer mostly by oral route, fail-safe, and are acceptable by society especially in developing countries. These vaccines are targeted to provide systemic as well as mucosal types of immunity. It has been predicted that in future children may get their immunization by munching on foods instead of getting enduring shots. The production of edible vaccines consists of the process of introducing the selected genes of desired quality into plant to induce these altered or transgenic plants to produce the encoded proteins in a natural way. These vaccines provide safer alternatives and help in reduction of cost of production and shipping and also decrease the potential hazards associated with conventional vaccines. However, becoming a reality and readily availability of edible vaccine is challenged by many problems of technical, regulatory, and nonscientific issues, which should be ruled out and rectified. This chapter provides insight into the current scenario and future applications of this new preventive modality.
Collapse
|
13
|
Seed Metabolome Analysis of a Transgenic Rice Line Expressing Cholera Toxin B-subunit. Sci Rep 2017; 7:5196. [PMID: 28701756 PMCID: PMC5507873 DOI: 10.1038/s41598-017-04701-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 05/19/2017] [Indexed: 02/07/2023] Open
Abstract
Plant-based human vaccines have been actively developed in recent years, and rice (Oryza sativa L.) is one of the best candidate crops for their production and delivery. By expressing a modified cholera toxin B (CTB) subunit, we previously developed MucoRice-CTB, a rice-based vaccine against cholera, which is caused by infection of the intestine with the bacteria Vibrio cholerae. MucoRice-CTB lines have been extensively characterized by whole-genome sequencing and proteome analyses to evaluate the mutation profiles and proteome status, respectively. Here, we report non-targeted metabolomic profiling of the MucoRice-CTB transgenic rice line 51A (MR-CTB51A), MucoRice-RNAi (MR-RNAi), and their non-transgenic parent line by using gas chromatography-time-of-flight mass spectrometry. The levels of several amino acids, organic acids, carbohydrates, lipids, and secondary metabolites were significantly increased in MR-CTB51A compared with the non-transgenic parent line. These metabolomics results complement essential information obtained by genome sequencing and proteomics approaches, thereby contributing to comprehensive understanding of the properties of MucoRice-CTB as a plant-based vaccine.
Collapse
|
14
|
The immunological characteristics and probiotic function of recombinant Bacillus subtilis spore expressing Clonorchis sinensis cysteine protease. Parasit Vectors 2016; 9:648. [PMID: 27993173 PMCID: PMC5170900 DOI: 10.1186/s13071-016-1928-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 12/04/2016] [Indexed: 12/23/2022] Open
Abstract
Background Clonorchiasis, a food-borne zoonosis, is caused by Clonorchis sinensis. The intestinal tract and bile ducts are crucial places for C. sinensis metacercariae to develop into adult worms. The endospore of Bacillus subtilis is an ideal oral immunization vehicle for delivery of heterologous antigens to intestine. Cysteine protease of C. sinensis (CsCP) is an endogenous key component in the excystment of metacercariae and other physiological or pathological processes. Methods We constructed a fusion gene of CotC (a coat protein)-CsCP and obtained B. subtilis spores with recombinant plasmid of pEB03-CotC-CsCP (B.s-CotC-CsCP). CotC-CsCP expressed on spores’ surface was detected by Western blotting and immunofluorescence. Immunological characteristics of recombinant spore coat protein were evaluated in a mouse model. The levels of CsCP-specific antibodies were detected by ELISA. Effects of recombinant spores on mouse intestine were evaluated by histological staining. The activities of biochemical enzymes in serum were assayed by microplate. Liver sections of infected mice were evaluated by Ishak score after Masson’s trichrome. Results The B.s-CotC-CsCP spores displayed CsCP on their coat. Specific IgG and isotypes were significantly induced by coat proteins of B.s-CotC-CsCP spores after subcutaneous immunization. IgA levels in intestinal mucus and bile of B.s-CotC-CsCP orally treated mice significantly increased. Additionally, more IgA-secreting cells were observed in enteraden and lamina propria regions of the mouse jejunum, and an increased amount of acidic mucins in intestines were also observed. There were no significant differences in enzyme levels of serum among groups. No inflammatory injury was observed in the intestinal tissues of each group. The degree of liver fibrosis was significantly reduced after oral immunization with B.s-CotC-CsCP spores. Conclusions Bacillus subtilis spores maintained the original excellent immunogenicity of CsCP expressed on their surface. Both local and systemic specific immune responses were elicited by oral administration of B.s-CotC-CsCP spores. The spores effectively promoted intestinal health by inducing secretion of acidic mucins, with no other side effects to the liver or intestine. Oral administration of spores expressing CsCP could provide effective protection against C. sinensis. This study may be a cornerstone for development of antiparasitic agents or vaccines against clonorchiasis based on B. subtilis spore expressing CsCP on the surface. Electronic supplementary material The online version of this article (doi:10.1186/s13071-016-1928-0) contains supplementary material, which is available to authorized users.
Collapse
|
15
|
Drake PMW, Szeto TH, Paul MJ, Teh AYH, Ma JKC. Recombinant biologic products versus nutraceuticals from plants - a regulatory choice? Br J Clin Pharmacol 2016; 83:82-87. [PMID: 27297459 DOI: 10.1111/bcp.13041] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 06/09/2016] [Accepted: 06/10/2016] [Indexed: 01/26/2023] Open
Abstract
Biotechnology has transformed the potential for plants to be a manufacturing source of pharmaceutical compounds. Now, with transgenic and transient expression techniques, virtually any biologic, including vaccines and therapeutics, could be manufactured in plants. However, uncertainty over the regulatory path for such new pharmaceuticals has been a deterrent. Consideration has been given to using alternative regulatory paths, including those for nutraceuticals or cosmetic agents. This review will consider these possibilities, and discuss the difficulties in establishing regulatory guidelines for new pharmaceutical manufacturing technologies.
Collapse
Affiliation(s)
- Pascal M W Drake
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Tim H Szeto
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Mathew J Paul
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Audrey Y-H Teh
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Julian K-C Ma
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| |
Collapse
|
16
|
Rossi L, Pinotti L, Agazzi A, Dell’Orto V, Baldi A. Plant Bioreactors for the Antigenic Hook-Associated flgK Protein Expression. ITALIAN JOURNAL OF ANIMAL SCIENCE 2016. [DOI: 10.4081/ijas.2014.2939] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
17
|
TUBERCULOSIS AND BRUCELLOSIS IN WOOD BISON (BISON BISON ATHABASCAE) IN NORTHERN CANADA: A RENEWED NEED TO DEVELOP OPTIONS FOR FUTURE MANAGEMENT. J Wildl Dis 2015; 51:543-54. [DOI: 10.7589/2014-06-167] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
18
|
Amaro MOF, Xisto MF, Dias ACF, Versiani AF, Cardoso SA, Otoni WC, da Silva CC, De Paula SO. Antigen production using heterologous expression of dengue virus-2 non-structural protein 1 (NS1) in Nicotiana tabacum (Havana) for immunodiagnostic purposes. PLANT CELL REPORTS 2015; 34:919-28. [PMID: 25689887 DOI: 10.1007/s00299-015-1753-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 01/08/2015] [Accepted: 01/21/2015] [Indexed: 06/04/2023]
Abstract
KEY MESSAGE Expression of dengue-2 virus NS1 protein in Nicotiana tabacum plants for development of dengue immunodiagnostic kits. Dengue is one of the most important diseases caused by arboviruses in the world. A significant increase in its geographical distribution has been noticed over the last 20 years, with continuous transmission of several serotypes and emergence of the hemorrhagic fever in areas where the disease was previously not prevalent. Although the methodological processes for dengue diagnosis are in deep development and improvement, a limitation for the realization of dengue diagnostic tests is the difficulty of large-scale production of the antigen to be used in diagnostic tests. Due to this demand, the purpose of this study was to obtain the non-structural protein 1 (NS1) from dengue-2 serotype by heterologous expression in Nicotiana tabacum (Havana). After confirmation of the NS1 protein gene integration in the plant genome, the heterologous protein was characterized using SDS-PAGE and immunoblotting. In an immunoenzymatic test, the recombinant NS1 protein presents an antigen potential for development of dengue immunodiagnostic kits.
Collapse
Affiliation(s)
- Marilane O F Amaro
- Laboratory of Molecular Immunovirology, Department of General Biology, Federal University of Viçosa, Av. PH Rolfs, s/n Campus Universitário, Viçosa, MG, CEP 36570-000, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Concentrated protein body product derived from rice endosperm as an oral tolerogen for allergen-specific immunotherapy--a new mucosal vaccine formulation against Japanese cedar pollen allergy. PLoS One 2015; 10:e0120209. [PMID: 25774686 PMCID: PMC4361645 DOI: 10.1371/journal.pone.0120209] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 01/20/2015] [Indexed: 01/07/2023] Open
Abstract
The endoplasmic reticulum-derived type-I protein body (PB-I) from rice endosperm cells is an ideal candidate formulation for the oral delivery of bioencapsulated peptides as tolerogens for allergen-specific immunotherapy. In the present study, PBs containing the deconstructed Japanese cedar pollen allergens Cryptomeria japonica 1 (Cry j 1) and Cry j 2 were concentrated by treatment with thermostable α-amylase at 90°C to remove the starch from milled rice powder, which resulted in a 12.5-fold reduction of dry weight compared to the starting material. The modified Cry j 1 and Cry j 2 antigens in this concentrated PB product were more resistant to enzymatic digestion than those in the milled seed powder despite the absence of intact cell wall and starch, and remained stable for at least 10 months at room temperature without detectable loss or degradation. The high resistance of these allergens could be attributed to changes in protein physicochemical properties induced by the high temperature concentration process, as suggested by the decreased solubility of the antigens and seed proteins in PBs in step-wise-extraction experiments. Confocal microscopy showed that the morphology of antigen-containing PB-Is was preserved in the concentrated PB product. The concentrated PB product induced specific immune tolerance against Cry j 1 and Cry j 2 in mice when orally administered, supporting its potential use as a novel oral tolerogen formulation.
Collapse
|
20
|
Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS 2015; 123:275-88. [PMID: 25630573 DOI: 10.1111/apm.12351] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 11/05/2014] [Indexed: 12/25/2022]
Abstract
Mucosal immune responses are the first-line defensive mechanisms against a variety of infections. Therefore, immunizations of mucosal surfaces from which majority of infectious agents make their entry, helps to protect the body against infections. Hence, vaccinization of mucosal surfaces by using mucosal vaccines provides the basis for generating protective immunity both in the mucosal and systemic immune compartments. Mucosal vaccines offer several advantages over parenteral immunization. For example, (i) ease of administration; (ii) non-invasiveness; (iii) high-patient compliance; and (iv) suitability for mass vaccination. Despite these benefits, to date, only very few mucosal vaccines have been developed using whole microorganisms and approved for use in humans. This is due to various challenges associated with the development of an effective mucosal vaccine that can work against a variety of infections, and various problems concerned with the safe delivery of developed vaccine. For instance, protein antigen alone is not just sufficient enough for the optimal delivery of antigen(s) mucosally. Hence, efforts have been made to develop better prophylactic and therapeutic vaccines for improved mucosal Th1 and Th2 immune responses using an efficient and safe immunostimulatory molecule and novel delivery carriers. Therefore, in this review, we have made an attempt to cover the recent advancements in the development of adjuvants and delivery carriers for safe and effective mucosal vaccine production.
Collapse
Affiliation(s)
- Atul Srivastava
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, India
| | | | | | | | | |
Collapse
|
21
|
Mucosal Vaccines from Plant Biotechnology. Mucosal Immunol 2015. [PMCID: PMC7158328 DOI: 10.1016/b978-0-12-415847-4.00065-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The use of plants for production of recombinant proteins has evolved over the past 25 years. The first plant-based vaccines were expressed in stably transgenic plants, with the idea to conveniently deliver “edible vaccines” by ingestion of the antigen-containing plant material. These systems provided a proof of concept that oral delivery of vaccines in crude plant material could stimulate antigen-specific serum and mucosal antibodies. Transgenic grains like rice in particular provide a stable and robust vehicle for antigen delivery. However, some issues exist with stably transgenic plants, including relatively low expression levels and regulatory issues. Thus, many recent studies use transient expression with plant viral vectors to achieve rapid high expression in Nicotiana benthamiana, followed by purification of antigen and intranasal delivery for effective stimulation of mucosal immune responses.
Collapse
|
22
|
Hassan SW, Waheed MT, Müller M, Clarke JL, Shinwari ZK, Lössl AG. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine. Hum Vaccin Immunother 2014; 10:2975-82. [PMID: 25483463 PMCID: PMC5443053 DOI: 10.4161/21645515.2014.970973] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Revised: 07/11/2014] [Accepted: 07/21/2014] [Indexed: 12/20/2022] Open
Abstract
Human Papillomavirus (HPV) is the main cause of cervical cancer, which is the second most severe cancer of women worldwide, particularly in developing countries. Although vaccines against HPV infection are commercially available, they are neither affordable nor accessible to women in low income countries e.g. Africa. Thus, alternative cost-effective vaccine production approaches need to be developed. This study uses tobacco plants to express pentameric capsomeres of HPV that have been reported to generate elevated immune responses against HPV. A modified HPV-16 L1 (L1_2xCysM) protein has been expressed as a fusion protein with glutathione-S-transferase (GST) in tobacco chloroplasts following biolistic transformation. In total 7 transplastomic lines with healthy phenotypes were generated. Site specific integration of the GST-L1_2xCysM and aadA genes was confirmed by PCR. Southern blot analysis verified homogenous transformation of all transplastomic lines. Antigen capture ELISA with the conformation-specific antibody Ritti01, showed protein expression as well as the retention of immunogenic epitopes of L1 protein. In their morphology, GST-L1 expressing tobacco plants were identical to wild type plants and yielded fertile flowers. Taken together, these data enrich knowledge for future development of cost-effective plant-made vaccines against HPV.
Collapse
Affiliation(s)
- Syed Waqas Hassan
- Department of Biotechnology; Quaid-i-Azam University; Islamabad, Pakistan
| | | | - Martin Müller
- Deutsches Krebsforschungszentrum; Heidelberg, Germany
| | - Jihong Liu Clarke
- Bioforsk-Norwegian Institute for Agricultural and Environmental Research; Aas, Norway
| | | | - Andreas Günter Lössl
- Department of Crop Sciences; University of Natural Resources and Applied Life Sciences; Tulln an der Donau, Austria
| |
Collapse
|
23
|
Jung M, Shin YJ, Kim J, Cha SB, Lee WJ, Shin MK, Shin SW, Yang MS, Jang YS, Kwon TH, Yoo HS. Induction of immune responses in mice and pigs by oral administration of classical swine fever virus E2 protein expressed in rice calli. Arch Virol 2014; 159:3219-30. [PMID: 25091740 DOI: 10.1007/s00705-014-2182-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 07/15/2014] [Indexed: 12/19/2022]
Abstract
Classical swine fever (CSF), caused by the CSF virus (CSFV), is a highly contagious disease in pigs. In Korea, vaccination using a live-attenuated strain (LOM strain) has been used to control the disease. However, parenteral vaccination using a live-attenuated strain still faces a number of problems related to storage, cost, injection stress, and differentiation of CSFV infected and vaccinated pigs. Therefore, two kinds of new candidates for oral vaccination have been developed based on the translation of the E2 gene of the SW03 strain, which was isolated from an outbreak of CSF in 2002 in Korea, in transgenic rice calli (TRCs) from Oriza sativa L. cv. Dongjin to express a recombinant E2 protein (rE2-TRCs). The expression of the recombinant E2 protein (rE2) in rE2-TRCs was confirmed using Northern blot, SDS-PAGE, and Western blot analysis. Immune responses to the rE2-TRC in mice and pigs were investigated after oral administration. The administration of rE2-TRCs increased E2-specific antibodies titers and antibody-secreting cells when compared to animals receiving the vector alone (p < 0.05 and p < 0.01). In addition, mice receiving rE2-TRCs had a higher level of CD8+ lymphocytes and Th1 cytokine immune responses to purified rE2 (prE2) in vitro than the controls (p < 0.05 and p < 0.01). Pigs receiving rE2-TRCs also showed an increase in IL-8, CCL2, and the CD8+ subpopulation in response to stimulation with prE2. These results suggest that oral administration of rE2-TRCs can induce E2-specific immune responses.
Collapse
Affiliation(s)
- Myunghwan Jung
- Department of Infectious diseases, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Rossi L, Dell'Orto V, Vagni S, Sala V, Reggi S, Baldi A. Protective effect of oral administration of transgenic tobacco seeds against verocytotoxic Escherichia coli strain in piglets. Vet Res Commun 2014; 38:39-49. [PMID: 24249478 DOI: 10.1007/s11259-013-9583-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/06/2013] [Indexed: 11/27/2022]
Abstract
The use of transgenic plants as delivery system for antigenic proteins is attractive for its simplicity and increases likelihood for local immune response at sites of infection. The aim of this study was to evaluate the protective effect of oral administration of tobacco seeds, expressing the FedA, the major protein of the F18 adhesive fimbriae, and B subunit of verocytotoxin, against verocytotoxin-producing E. coli (VTEC) strain in piglets. Forty-three early weaned piglets, were randomly divided into 4 experimental groups: 3 test groups and a control. Treatment groups orally received a bolus, with different dose of tobacco seeds on 0, 1, 2, 14 days post primary administration. After challenge, with 1*10(10) CFU of O138 Escherichia coli strain, piglets showed clinical scores significantly higher in the control group compared to orally immunized groups (P < 0.05) and the latter showed a faster recovery than in CG. In conclusion, oral administration of recombinant tobacco seeds expressing antigenic proteins against VTEC strains can induce a protective effect against challenger strain in piglets.
Collapse
Affiliation(s)
- Luciana Rossi
- Department of Health, Animal Science and Food Safety, Università di Milano, Via Celoria 10, 20133, Milan, Italy,
| | | | | | | | | | | |
Collapse
|
25
|
Rahal A, . M, Verma AK, . AK, . RT, . SK, . SC, . KD. Phytonutrients and Nutraceuticals in Vegetables and Their Multi-dimensional Medicinal and Health Benefits for Humans and Their Companion Animals: A Review. ACTA ACUST UNITED AC 2013. [DOI: 10.3923/jbs.2014.1.19] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
26
|
Tombácz K, Gellért Á, Salánki K, Balázs E, Tuboly T. Oral immunogenicity of a plant virus vector based porcine circovirus antigen - short communication. Acta Vet Hung 2013; 61:547-52. [PMID: 23974938 DOI: 10.1556/avet.2013.044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A recombinant cucumber mosaic virus based expression system has been developed for the production of an immunogenic porcine circovirus epitope. The resulting nanoparticle was shown to elicit specific immune response in mice and pigs, when administered parenterally. To evaluate the oral applicability of this vaccine candidate, two experiments were performed. In the first one, the resistance of the vector itself to mucosal environment was tested in mice. Cucumber mosaic virus particles fed to mice were able to elicit specific mucosal and serum antibody production. In the second experiment, recombinant cucumber mosaic virus fed to piglets resulted in the appearance of porcine circovirus specific serum antibodies. The vector proved to be able to survive in the gastrointestinal tract, so that an epitope expressed on its surface could induce specific immune response. These results indicate that the developed plant virus based expression system offers an effective method for mucosal vaccine production.
Collapse
Affiliation(s)
- Kata Tombácz
- 1 Szent István University Department of Microbiology and Infectious Diseases, Faculty of Veterinary Science Hungária krt. 23-25 H-1143 Budapest Hungary
| | - Ákos Gellért
- 2 Centre for Agricultural Research Department of Applied Genomics, Agricultural Institute Martonvásár Hungary
| | | | - Ervin Balázs
- 2 Centre for Agricultural Research Department of Applied Genomics, Agricultural Institute Martonvásár Hungary
| | - Tamás Tuboly
- 1 Szent István University Department of Microbiology and Infectious Diseases, Faculty of Veterinary Science Hungária krt. 23-25 H-1143 Budapest Hungary
| |
Collapse
|
27
|
Hefferon K. Plant-derived pharmaceuticals for the developing world. Biotechnol J 2013; 8:1193-202. [PMID: 23857915 DOI: 10.1002/biot.201300162] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Revised: 04/02/2013] [Accepted: 06/26/2013] [Indexed: 12/17/2022]
Abstract
Plant-produced vaccines and therapeutic agents offer enormous potential for providing relief to developing countries by reducing the incidence of infant mortality caused by infectious diseases. Vaccines derived from plants have been demonstrated to effectively elicit an immune response. Biopharmaceuticals produced in plants are inexpensive to produce, require fewer expensive purification steps, and can be stored at ambient temperatures for prolonged periods of time. As a result, plant-produced biopharmaceuticals have the potential to be more accessible to the rural poor. This review describes current progress with respect to plant-produced biopharmaceuticals, with a particular emphasis on those that target developing countries. Specific emphasis is given to recent research on the production of plant-produced vaccines toward human immunodeficiency virus, malaria, tuberculosis, hepatitis B virus, Ebola virus, human papillomavirus, rabies virus and common diarrheal diseases. Production platforms used to express vaccines in plants, including nuclear and chloroplast transformation, and the use of viral expression vectors, are described in this review. The review concludes by outlining the next steps for plant-produced vaccines to achieve their goal of providing safe, efficacious and inexpensive vaccines to the developing world.
Collapse
Affiliation(s)
- Kathleen Hefferon
- Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada; Cornell University, Ithaca, NY, USA.
| |
Collapse
|
28
|
Kwon KC, Verma D, Singh ND, Herzog R, Daniell H. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev 2013; 65:782-99. [PMID: 23099275 PMCID: PMC3582797 DOI: 10.1016/j.addr.2012.10.005] [Citation(s) in RCA: 94] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Revised: 09/26/2012] [Accepted: 10/17/2012] [Indexed: 12/19/2022]
Abstract
Among 12billion injections administered annually, unsafe delivery leads to >20million infections and >100million reactions. In an emerging new concept, freeze-dried plant cells (lettuce) expressing vaccine antigens/biopharmaceuticals are protected in the stomach from acids/enzymes but are released to the immune or blood circulatory system when plant cell walls are digested by microbes that colonize the gut. Vaccine antigens bioencapsulated in plant cells upon oral delivery after priming, conferred both mucosal and systemic immunity and protection against bacterial, viral or protozoan pathogens or toxin challenge. Oral delivery of autoantigens was effective against complications of type 1 diabetes and hemophilia, by developing tolerance. Oral delivery of proinsulin or exendin-4 expressed in plant cells regulated blood glucose levels similar to injections. Therefore, this new platform offers a low cost alternative to deliver different therapeutic proteins to combat infectious or inherited diseases by eliminating inactivated pathogens, expensive purification, cold storage/transportation and sterile injections.
Collapse
Affiliation(s)
- Kwang-Chul Kwon
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816-2364, USA
| | - Dheeraj Verma
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816-2364, USA
| | - Nameirakpam D. Singh
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816-2364, USA
| | - Roland Herzog
- Department of Pediatrics, College of Medicine, University of Florida, Cancer and Genetics Research Complex, 2033 Mowry Road, Gainesville, FL 32610, USA
| | - Henry Daniell
- Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816-2364, USA
| |
Collapse
|
29
|
Festa M, Brun P, Piccinini R, Castagliuolo I, Basso B, Zecconi A. Staphylococcus aureus Efb protein expression in Nicotiana tabacum and immune response to oral administration. Res Vet Sci 2013; 94:484-9. [PMID: 23158852 DOI: 10.1016/j.rvsc.2012.10.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Revised: 10/16/2012] [Accepted: 10/20/2012] [Indexed: 10/27/2022]
Abstract
Staphylococcus aureus (S. aureus) is one of the most widespread agent of diseases in humans and animals. In dairy cows, S. aureus is the most frequently isolated contagious pathogens in mastitis cases and vaccines are one of the potential tools to control the infections, thus decreasing the use of antibiotics. Among all the virulence factors produced by S. aureus, extra cellular fibrinogen binding protein (Efb) is an important one in the pathogenesis of mastitis. Plants are useful bioreactors to produce antigens and the aim of the study was the production of Efb in two cultivars of Nicotiana tabacum as a mean to produce vaccine against S. aureus in plants. A matrix attachment region (MAR) sequence was inserted near the two borders of transfer-DNA in the transformation vector in the two possible orientations. The presence of MAR elements in the transformation system significantly improved transformation efficiency and Efb protein yield up to a 2% level on total soluble protein (TSP). Mice orally immunized with transgenic lyophilized leaves produced an antigen-specific immune response.
Collapse
Affiliation(s)
- Margherita Festa
- Institute of Biophysics CNR-Dept. Life Sciences, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy
| | | | | | | | | | | |
Collapse
|
30
|
Wang S, Takahashi H, Kajiura H, Kawakatsu T, Fujiyama K, Takaiwa F. Transgenic rice seeds accumulating recombinant hypoallergenic birch pollen allergen Bet v 1 generate giant protein bodies. PLANT & CELL PHYSIOLOGY 2013; 54:917-33. [PMID: 23539245 DOI: 10.1093/pcp/pct043] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
A versatile hypoallergenic allergen derivative against multiple allergens is an ideal tolerogen for allergen-specific immunotherapy. Such a tolerogen should exhibit high efficacy, without side effects, when administered at high doses and should be applicable to several allergens. Tree pollen chimera 7 (TPC7), a hypoallergenic Bet v 1 tolerogen against birch pollen allergy, was previously selected by DNA shuffling of 14 types of Fagales tree pollen allergens. In this study, transgenic rice seed accumulating TPC7 was generated as an oral vaccine against birch pollen allergy by expressing this protein as a secretory protein using the N-terminal signal peptide and the C-terminal KDEL tag under the control of an endosperm-specific glutelin promoter. The highest level of TPC7 accumulation was approximately 207 µg grain(-1). Recombinant TPC7 is a glycoprotein with high mannose-type N-glycan, but without β1,2-xylose or α1,3-fucose, suggesting that TPC7 is retained in the endoplasmic reticulum (ER). TPC7 is deposited as a novel, giant spherical ER-derived protein body, >20 µm in diameter, which is referred to as the TPC7 body. Removal of the KDEL retention signal or mutation of a cysteine residue resulted in an alteration of TPC7 body morphology, and deletion of the signal peptide prevented the accumulation of TPC7 in rice seeds. Therefore, the novel TPC7 bodies may have formed aggregates within the ER lumen, primarily due to the intrinsic physicochemical properties of the protein.
Collapse
Affiliation(s)
- Shuyi Wang
- Functional Transgenic Crops Research Unit, Genetically Modified Organism Research Center, National Institute of Agrobiological Sciences, Kannondai 2-1-2, Tsukuba, Ibaraki, 305-8602 Japan
| | | | | | | | | | | |
Collapse
|
31
|
Asensi GF, de Sales NFF, Dutra FF, Feijó DF, Bozza MT, Ulrich RG, Miyoshi A, de Morais K, Azevedo VADC, Silva JT, Le Loir Y, Paschoalin VMF. Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. Microb Cell Fact 2013; 12:32. [PMID: 23561053 PMCID: PMC3623888 DOI: 10.1186/1475-2859-12-32] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2012] [Accepted: 03/22/2013] [Indexed: 11/14/2022] Open
Abstract
Background Staphylococcus aureus is unrestrictedly found in humans and in animal species that maintain thermal homeostasis. Inadequate cleaning of processing equipment or inappropriate handling can contaminate processed food and cause severe food poisoning. Staphylococcal enterotoxin B (SEB), a potent superantigenic exotoxin, is produced by 50% of clinical isolates of S. aureus and is associated with massive food poisoning and with the induction of toxic shock syndrome. Results A gene sequence encoding a recombinant SEB (rSEB), devoid of superantigenic activity, was successfully cloned and expressed in a cytoplasmic or a secreted form in the food-grade lactic acid bacterium Lactococcus lactis. The recombinant protein detected in the cytoplasm or in the culture medium exhibited the expected molecular mass and was recognized by a SEB-polyclonal antibody. Oral immunization with the recombinant L. lactis strains induced a protective immune response in a murine model of S. aureus infection. Immunized mice survived intraperitoneal challenge with an S. aureus SEB-producer strain. Counts of S. aureus in the spleen of rSEB-immunized mice were significantly reduced. The rSEB-immunized mice showed significant titers of anti-SEB IgA and IgG in stools and serum, respectively. Both recombinant L. lactis strains were able to elicit cellular or systemic immune responses in mice, with no significant difference if rSEB was produced in its cytoplasmic or secreted form. However, recombinant L. lactis expressing the cytoplasmic rSEB increased the survival rate of the challenged mice by 43%. Conclusions These findings show the vaccine efficacy of L. lactis carrying an attenuated SEB, in a murine model, following lethal S. aureus challenge.
Collapse
|
32
|
Takaiwa F. Update on the use of transgenic rice seeds in oral immunotherapy. Immunotherapy 2013; 5:301-12. [DOI: 10.2217/imt.13.4] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Rice seed provides an ideal production platform for pharmaceuticals in terms of high productivity and stability, as well as the scalability, safety and economy that are expected in plant production systems. Furthermore, these therapeutic products are bioencapsulated in protein bodies, which are seed-specific storage organelles that provide protection from digestion by gastrointestinal enzymes during delivery to the gut-associated lymphoid tissue. Thus, rice seed provides an ideal delivery system for the mucosal immune system. Oral immunotherapy using unprocessed transgenic rice seed containing therapeutic products has been demonstrated to induce effective mucosal immune tolerance and immune reactions against allergies and pathogens.
Collapse
Affiliation(s)
- Fumio Takaiwa
- Functional Transgenic Crop Research Unit, National Institute of Agrobiological Sciences, Kannondai 2–1–2, Tsukuba, Ibaraki 305-8602, Japan
| |
Collapse
|
33
|
Jacob SS, Cherian S, Sumithra TG, Raina OK, Sankar M. Edible vaccines against veterinary parasitic diseases--current status and future prospects. Vaccine 2013; 31:1879-85. [PMID: 23485715 DOI: 10.1016/j.vaccine.2013.02.022] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2013] [Revised: 02/02/2013] [Accepted: 02/11/2013] [Indexed: 12/17/2022]
Abstract
Protection of domestic animals against parasitic infections remains a major challenge in most of the developing countries, especially in the surge of drug resistant strains. In this circumstance vaccination seems to be the sole practical strategy to combat parasites. Most of the presently available live or killed parasitic vaccines possess many disadvantages. Thus, expression of parasitic antigens has seen a continued interest over the past few decades. However, only a limited success was achieved using bacterial, yeast, insect and mammalian expression systems. This is witnessed by an increasing number of reports on transgenic plant expression of previously reported and new antigens. Oral delivery of plant-made vaccines is particularly attractive due to their exceptional advantages. Moreover, the regulatory burden for veterinary vaccines is less compared to human vaccines. This led to an incredible investment in the field of transgenic plant vaccines for veterinary purpose. Plant based vaccine trials have been conducted to combat various significant parasitic diseases such as fasciolosis, schistosomosis, poultry coccidiosis, porcine cycticercosis and ascariosis. Besides, passive immunization by oral delivery of antibodies expressed in transgenic plants against poultry coccidiosis is an innovative strategy. These trials may pave way to the development of promising edible veterinary vaccines in the near future. As the existing data regarding edible parasitic vaccines are scattered, an attempt has been made to assemble the available literature.
Collapse
Affiliation(s)
- Siju S Jacob
- Division of Parasitology, Indian Veterinary Research Institute, Izatnagar 243122, UP, India.
| | | | | | | | | |
Collapse
|
34
|
The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects? Int J Mol Sci 2013; 14:1978-98. [PMID: 23337199 PMCID: PMC3565360 DOI: 10.3390/ijms14011978] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Revised: 01/07/2013] [Accepted: 01/14/2013] [Indexed: 01/20/2023] Open
Abstract
Hepatitis B persists as a common human disease despite effective vaccines having been employed for almost 30 years. Plants were considered as alternative sources of vaccines, to be mainly orally administered. Despite 20-year attempts, no real anti-HBV plant-based vaccine has been developed. Immunization trials, based on ingestion of raw plant tissue and conjugated with injection or exclusively oral administration of lyophilized tissue, were either impractical or insufficient due to oral tolerance acquisition. Plant-produced purified HBV antigens were highly immunogenic when injected, but their yields were initially insufficient for practical purposes. However, knowledge and technology have progressed, hence new plant-derived anti-HBV vaccines can be proposed today. All HBV antigens can be efficiently produced in stable or transient expression systems. Processing of injection vaccines has been developed and needs only to be successfully completed. Purified antigens can be used for injection in an equivalent manner to the present commercial vaccines. Although oral vaccines require improvement, plant tissue, lyophilized or extracted and converted into tablets, etc., may serve as a boosting vaccine. Preliminary data indicate also that both vaccines can be combined in an effective parenteral-oral immunization procedure. A partial substitution of injection vaccines with oral formulations still offers good prospects for economically viable and efficacious anti-HBV plant-based vaccines.
Collapse
|
35
|
Skarjinskaia M, Ruby K, Araujo A, Taylor K, Gopalasamy-Raju V, Musiychuk K, Chichester JA, Palmer GA, de la Rosa P, Mett V, Ugulava N, Streatfield SJ, Yusibov V. Hairy Roots as a Vaccine Production and Delivery System. BIOTECHNOLOGY OF HAIRY ROOT SYSTEMS 2013; 134:115-34. [DOI: 10.1007/10_2013_184] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
36
|
Chen Q, Lai H. Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother 2013; 9:26-49. [PMID: 22995837 PMCID: PMC3667944 DOI: 10.4161/hv.22218] [Citation(s) in RCA: 105] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2012] [Revised: 09/06/2012] [Accepted: 09/13/2012] [Indexed: 02/07/2023] Open
Abstract
Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that mimic the native architecture of viruses but lack the viral genome. VLPs have emerged as a premier vaccine platform due to their advantages in safety, immunogenicity, and manufacturing. The particulate nature and high-density presentation of viral structure proteins on their surface also render VLPs as attractive carriers for displaying foreign epitopes. Consequently, several VLP-based vaccines have been licensed for human use and achieved significant clinical and economical success. The major challenge, however, is to develop novel production platforms that can deliver VLP-based vaccines while significantly reducing production times and costs. Therefore, this review focuses on the essential role of plants as a novel, speedy and economical production platform for VLP-based vaccines. The advantages of plant expression systems are discussed in light of their distinctive posttranslational modifications, cost-effectiveness, production speed, and scalability. Recent achievements in the expression and assembly of VLPs and their chimeric derivatives in plant systems as well as their immunogenicity in animal models are presented. Results of human clinical trials demonstrating the safety and efficacy of plant-derived VLPs are also detailed. Moreover, the promising implications of the recent creation of "humanized" glycosylation plant lines as well as the very recent approval of the first plant-made biologics by the U. S. Food and Drug Administration (FDA) for plant production and commercialization of VLP-based vaccines are discussed. It is speculated that the combined potential of plant expression systems and VLP technology will lead to the emergence of successful vaccines and novel applications of VLPs in the near future.
Collapse
Affiliation(s)
- Qiang Chen
- Center for Infectious Diseases and Vaccinology, Biodesign Institute at Arizona State University, Tempe, AZ USA.
| | | |
Collapse
|
37
|
Matvieieva NA, Kudryavets YI, Likhova AA, Shakhovskij AM, Bezdenezhnykh NA, Kvasko EY. Antiviral activity of extracts of transgenic chicory and lettuce plants with the human interferon α2b gene. CYTOL GENET+ 2012. [DOI: 10.3103/s0095452712050076] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Overview of plant-made vaccine antigens against malaria. J Biomed Biotechnol 2012; 2012:206918. [PMID: 22911156 PMCID: PMC3403509 DOI: 10.1155/2012/206918] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2012] [Revised: 05/22/2012] [Accepted: 05/23/2012] [Indexed: 11/18/2022] Open
Abstract
This paper is an overview of vaccine antigens against malaria produced in plants. Plant-based expression systems represent an interesting production platform due to their reduced manufacturing costs and high scalability. At present, different Plasmodium antigens and expression strategies have been optimized in plants. Furthermore, malaria antigens are one of the few examples of eukaryotic proteins with vaccine value expressed in plants, making plant-derived malaria antigens an interesting model to analyze. Up to now, malaria antigen expression in plants has allowed the complete synthesis of these vaccine antigens, which have been able to induce an active immune response in mice. Therefore, plant production platforms offer wonderful prospects for improving the access to malaria vaccines.
Collapse
|
39
|
Matvieieva NA, Shakhovskij AM, Kuchuk MV. Features of lettuce transgenic plants with the ifn-α2b gene regenerated after Agrobacterium rhizogenes-mediated transformation. CYTOL GENET+ 2012. [DOI: 10.3103/s0095452712030073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Abstract
During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.
Collapse
Affiliation(s)
- H S Mason
- Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
| | | |
Collapse
|
41
|
Wang Y, Shen Q, Jiang Y, Song Y, Fang L, Xiao S, Chen H. Immunogenicity of foot-and-mouth disease virus structural polyprotein P1 expressed in transgenic rice. J Virol Methods 2012; 181:12-7. [DOI: 10.1016/j.jviromet.2012.01.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 12/23/2011] [Accepted: 01/09/2012] [Indexed: 11/25/2022]
|
42
|
Khan I, Twyman RM, Arcalis E, Stoger E. Using storage organelles for the accumulation and encapsulation of recombinant proteins. Biotechnol J 2012; 7:1099-108. [DOI: 10.1002/biot.201100089] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2011] [Revised: 01/18/2012] [Accepted: 02/06/2012] [Indexed: 11/06/2022]
|
43
|
Pelosi A, Shepherd R, Walmsley AM. Delivery of plant-made vaccines and therapeutics. Biotechnol Adv 2012; 30:440-8. [DOI: 10.1016/j.biotechadv.2011.07.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 07/14/2011] [Accepted: 07/25/2011] [Indexed: 11/17/2022]
|
44
|
Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2011; 18:2031-7. [PMID: 22012978 PMCID: PMC3232705 DOI: 10.1128/cvi.05352-11] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Accepted: 09/15/2011] [Indexed: 01/03/2023]
Abstract
While Crimean-Congo hemorrhagic fever (CCHF) has a high mortality rate in humans, the associated virus (CCHFV) does not induce clinical symptoms in animals, but animals play an important role in disease transmission to humans. Our aim in this study was to examine the immunogenicity of the CCHFV glycoprotein when expressed in the root and leaf of transgenic plants via hairy roots and stable transformation of tobacco plants, respectively. After confirmatory analyses of transgenic plant lines and quantification of the expressed glycoprotein, mice were either fed with the transgenic leaves or roots, fed the transgenic plant material and injected subcutaneously with the plant-made CCHFV glycoprotein (fed/boosted), vaccinated with an attenuated CCHF vaccine (positive control), or received no treatment (negative control). All immunized groups had a consistent rise in anti-glycoprotein IgG and IgA antibodies in their serum and feces, respectively. The mice in the fed/boosted group showed a significant rise in specific IgG antibodies after a single boost. Our results imply that oral immunization of animals with edible materials from transgenic plants is feasible, and further assessments are under way. In addition, while the study of CCHF is challenging, our protocol should be further used to study CCHFV infection in the knockout mouse model and virus neutralization assays in biosafety level 4 laboratories.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antibodies, Viral/analysis
- Antibodies, Viral/blood
- Feces/chemistry
- Glycoproteins/genetics
- Glycoproteins/immunology
- Hemorrhagic Fever Virus, Crimean-Congo/genetics
- Hemorrhagic Fever Virus, Crimean-Congo/immunology
- Immunoglobulin A/analysis
- Immunoglobulin G/blood
- Mice
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/immunology
- Serum/chemistry
- Serum/immunology
- Nicotiana
- Vaccines, Edible
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Viral Proteins/genetics
- Viral Proteins/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/genetics
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- S. M. Ghiasi
- Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - A. H. Salmanian
- Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - S. Chinikar
- Arboviruses and Viral Hemorrhagic Fevers Laboratory (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran
| | - S. Zakeri
- Malaria Research Group, Biotechnology and Vector Research Center, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
45
|
Suzuki K, Kaminuma O, Yang L, Takai T, Mori A, Umezu-Goto M, Ohtomo T, Ohmachi Y, Noda Y, Hirose S, Okumura K, Ogawa H, Takada K, Hirasawa M, Hiroi T, Takaiwa F. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. PLANT BIOTECHNOLOGY JOURNAL 2011; 9:982-990. [PMID: 21447056 DOI: 10.1111/j.1467-7652.2011.00613.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This study tested the feasibility of oral immunotherapy for bronchial asthma using a newly developed subunit vaccine in which a fragment (p45-145) of mite allergen (Der p 1) containing immunodominant human and mouse T cell epitopes was encapsulated in endoplasmic reticulum-derived protein bodies of transgenic (Tg) rice seed. Allergen-specific serum immunoglobulin responses, T cell proliferation, Th1/Th2 cytokine production, airway inflammatory cell infiltration, bronchial hyper-responsiveness (BHR) and lung histology were investigated in allergen-immunized and -challenged mice. Prophylactic oral vaccination with the Tg rice seeds clearly reduced the serum levels of allergen-specific IgE and IgG. Allergen-induced CD4(+) T cell proliferation and production of Th2 cytokines in vitro, infiltration of eosinophils, neutrophils and mononuclear cells into the airways and BHR were also inhibited by oral vaccination. The effects of the vaccine were antigen-specific immune response because the levels of specific IgE and IgG in mice immunized with Der f 2 or ovalbumin were not significantly suppressed by oral vaccination with the Der p 1 expressing Tg rice. Thus, the vaccine does not induce nonspecific bystander suppression, which has been a problem with many oral tolerance regimens. These results suggest that our novel vaccine strategy is a promising approach for allergen-specific oral immunotherapy against allergic diseases including bronchial asthma.
Collapse
MESH Headings
- Animals
- Antibody Formation
- Antigens, Dermatophagoides/genetics
- Antigens, Dermatophagoides/immunology
- Antigens, Dermatophagoides/metabolism
- Arthropod Proteins/genetics
- Arthropod Proteins/immunology
- Arthropod Proteins/metabolism
- Asthma/immunology
- Asthma/prevention & control
- Asthma/therapy
- Bystander Effect
- Cell Proliferation
- Cysteine Endopeptidases/genetics
- Cysteine Endopeptidases/immunology
- Cysteine Endopeptidases/metabolism
- Desensitization, Immunologic
- Epitopes, T-Lymphocyte/immunology
- Female
- Humans
- Immunity, Cellular
- Immunoglobulin E/immunology
- Lung/immunology
- Lung/pathology
- Mice
- Mice, Inbred BALB C
- Oryza/genetics
- Oryza/immunology
- Oryza/metabolism
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/immunology
- Plants, Genetically Modified/metabolism
- Plasmids/genetics
- Plasmids/metabolism
- Pyroglyphidae/immunology
- Seeds/genetics
- Seeds/immunology
- Seeds/metabolism
- Vaccination
- Vaccines, Edible/administration & dosage
- Vaccines, Edible/immunology
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/immunology
Collapse
Affiliation(s)
- Kazuya Suzuki
- Transgenic Crop Research and Development Center, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Sandolo C, Péchiné S, Le Monnier A, Hoys S, Janoir C, Coviello T, Alhaique F, Collignon A, Fattal E, Tsapis N. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur J Pharm Biopharm 2011; 79:566-73. [DOI: 10.1016/j.ejpb.2011.05.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Revised: 05/19/2011] [Accepted: 05/24/2011] [Indexed: 11/27/2022]
|
47
|
Matvieieva NA, Kishchenko OM, Potrochov AO, Shakhovsky AM, Kuchuk MV. Regeneration of transgenic plants from hairy roots of Cichorium intybus L. var. Foliosum Hegi. CYTOL GENET+ 2011. [DOI: 10.3103/s0095452711050082] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Noris E, Poli A, Cojoca R, Rittà M, Cavallo F, Vaglio S, Matic S, Landolfo S. A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions. Arch Virol 2011; 156:587-95. [PMID: 21234770 DOI: 10.1007/s00705-010-0893-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2010] [Accepted: 12/14/2010] [Indexed: 01/13/2023]
Abstract
We investigated the potential of Nicotiana benthamiana to express the E7 protein of human papillomavirus 8 (HPV-8), a paradigm genotype among cutaneous HPVs. The protein, modified in its putative pRb-binding domain (E7(QGD)), was transiently expressed in leaves following infiltration with agrobacteria carrying either a binary vector combined with silencing suppressor constructs or replicating tobacco mosaic virus (TMV)-based vectors with different targeting signals. HPV-8 E7(QGD) yields ranged from 250 ng to 4.6 mg per gram of fresh leaf tissue. The highest yields were obtained with TMV-based vectors targeting the antigen to the apoplast. HPV8-CER (H2(q)) mice transformed with the complete early region of HPV-8 showed a delay in the onset of skin papillomatous lesions and produced E7-specific immunoglobulins G when inoculated subcutaneously with leaf extracts expressing E7(QGD). Furthermore, we demonstrated that the plant-made HPV-8 E7(QGD) induced a specific cytotoxic response in C57BL/6 (H2(b)) mice.
Collapse
Affiliation(s)
- Emanuela Noris
- Istituto di Virologia Vegetale, Consiglio Nazionale delle Ricerche, Strada delle Cacce 73, Turin, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Seo KW, Kim DH, Kim AH, Yoo HS, Lee KY, Jang YS. Characterization of Antigenic Determinants in ApxIIA Exotoxin Capable of Inducing Protective Immunity toActinobacillus pleuropneumoniaeChallenge. Immunol Invest 2011; 40:465-80. [DOI: 10.3109/08820139.2011.558151] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
50
|
Matvieieva NA, Vasylenko MY, Shahovsky AM, Bannykova MO, Kvasko OY, Kuchuk NV. Effective Agrobacterium-mediated transformation of chicory (Cichorium intybus L.) with Mycobacterium tuberculosis antigene ESAT6. CYTOL GENET+ 2011. [DOI: 10.3103/s0095452711010038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|